Systematic Review

Efficacy and safety of chimeric antigen receptor T cell immunotherapy in B-cell non-Hodgkin lymphoma: a systematic review and meta-analysis

Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China

Search for more papers by this author

Yunchong Meng

Department of Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China

Search for more papers by this author

Yaohui Wu

Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China

Search for more papers by this author

Jing He

Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China

Search for more papers by this author

Fang Liu

*Author for correspondence:

E-mail Address: liufang19961996@163.com

Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China

Search for more papers by this author

Published Online:7 Jan 2021https://doi.org/10.2217/imt-2020-0221

View article

Abstract

Aim: The aim was to evaluate the efficacy and safety of chimeric antigen receptor T (CAR-T) cell in B-cell non-Hodgkin lymphoma (B-NHL). Materials & methods: A meta-analysis was conducted using eligible clinical trials, which were obtained from electronic medical literature databases. Results: A total of 24 clinical trials with 590 patients were included. The best overall response rate was 66% and complete remission rate was 46%. The incidence rates of cytokine-release syndrome and neurotoxicity (grade ≥ 3) were 9 and 5%, respectively. The various clinical factors were analyzed. Autogenic CAR-T cell may lead to improved efficacy than allogeneic CAR-T cell. CD20 CAR-T cell may show increased efficacy than CD19 CAR-T cell. Conclusion: CAR-T immunotherapy has remarkable efficacy and low toxicity in relapsed/refractory B-NHL.

Lay abstract

Immunotherapy has demonstrated remarkable antitumor activity in the field of lymphoma (a type of blood cancer that develops when white blood cells grow out of control) compared with conventional treatment methods. Simultaneously, the toxicity associated with immunotherapy is attracting the attention of researchers. We conducted a study to further reveal the effectiveness and safety of an emerging immunotherapy method to treat lymphoma. We analyze several clinical factors that may affect the outcome of treatment, hoping to provide useful information with regards to the treatment of lymphoma. Our results indicated that this emerging immunotherapy method has remarkable efficacy and low toxicity in lymphoma.

Keywords:

Papers of special note have been highlighted as: • of interest

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018).
MedlineGoogle Scholar
2. Al-Hamadani M, Habermann TM, Cerhan JR, Macon WR, Maurer MJ, Go RS. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011. Am. J. Hematol. 90(9), 790–795 (2015).
MedlineGoogle Scholar
3. Jacoby E, Shahani SA, Shah NN. Updates on CAR T-cell therapy in B-cell malignancies. Immunol. Rev. 290(1), 39–59 (2019).
Medline CASGoogle Scholar
4. Chavez JC, Bachmeier C, Kharfan-Dabaja MA. CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products. Ther. Adv. Hematol. 10, 1–20 (2019).
Google Scholar
5. Salter AI, Pont MJ, Riddell SR. Chimeric antigen receptor-modified T cells: CD19 and the road beyond. Blood 131(24), 2621–2629 (2018).
Medline CASGoogle Scholar
6. Brudno JN, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for lymphoma. Nat. Rev. Clin. Oncol. 15(1), 31–46 (2018).
Medline CASGoogle Scholar
7. Wang Z, Wu Z, Liu Y, Han W. New development in CAR-T cell therapy. J. Hematol. Oncol. 10(1), 53 (2017).
MedlineGoogle Scholar
8. Chavez JC, Locke FL. CAR-T cell therapy for B-cell lymphomas. Best Pract. Res. Clin. Haematol. 31(2), 135–146 (2018).
MedlineGoogle Scholar
9. Till BG, Jensen MC, Wang J et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 119(17), 3940–3950 (2012).
Medline CASGoogle Scholar
10. Wang Y, Zhang WY, Han QW et al. Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. Clin. Immunol. 155(2), 160–175 (2014).
Medline CASGoogle Scholar
11. Zhang WY, Wang Y, Guo YL et al. Treatment of CD20-directed chimeric antigen receptor-modified T cells in patients with relapsed or refractory b-cell non-hodgkin lymphoma: an early Phase IIa trial report. Signal Transduct. Target Ther. 1, 16002 (2016).
MedlineGoogle Scholar
12. Haso W, Lee DW, Shah NN et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 121(7), 165–1174 (2013).
Google Scholar
13. Ramos CA, Ballard B, Zhang H et al. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J. Clin. Invest. 127(9), 3462–3471 (2017).
MedlineGoogle Scholar
14. Ramos CA, Savoldo B, Torrano V et al. Clinical responses with T lymphocytes targeting malignancy-associated kappa light chains. J. Clin. Invest. 126(7), 2588–2596 (2016).
MedlineGoogle Scholar
15. Locke FL, Neelapu SS, Bartlett NL et al. Phase I results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR-T cell therapy in refractory aggressive lymphoma. Mol. Ther. 25(1), 285–295 (2017). • A multicenter ZUMA-1 Phase I study evaluates KTE-C19 in patients with refractory diffuse large B-cell lymphoma and this is the first multicenter study of anti-CD19 chimeric antigen receptor T (CAR-T) cell therapy in patients with non-Hodgkin lymphoma.
Medline CASGoogle Scholar
16. Neelapu SS, Locke FL, Bartlett NL et al. Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma. N. Engl. J. Med. 377(26), 2531–2544 (2017). • A multicenter Phase II study of axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma and indicated that CAR T-cell therapy had high levels of durable response in these patients.
Medline CASGoogle Scholar
17. Schuster SJ, Bishop MR, Tam CS et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380(1), 45–56 (2019). • An international Phase II pivotal study of tisagenlecleucel in patients with relapsed or refractory diffuse large B-cell lymphoma and indicated high rates of durable responses with the use of tisagenlecleucel.
Medline CASGoogle Scholar
18. Zheng XH, Zhang XY, Dong QQ, Chen F, Yang SB, Li WB. Efficacy and safety of chimeric antigen receptor-T cells in the treatment of B cell lymphoma: a systematic review and meta-analysis. Chin. Med. J. (Engl). 133(1), 74–85 (2020).
MedlineGoogle Scholar
19. Cao G, Lei L, Zhu X. Efficiency and safety of autologous chimeric antigen receptor T-cells therapy used for patients with lymphoma. Medicine (Baltimore) 98(42), e17506 (2019). • A meta-analysis of 241 patients from 16 studies indicates that the best overall response rate (ORR) of CAR-T therapy for lymphoma was 71%, the overall rate of severe CRS was 26%, and the no IL-2 group had a better best ORR and more durable 6 m ORR than the IL-2 group.
Medline CASGoogle Scholar
20. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4), 1088–1101 (1994).
Medline CASGoogle Scholar
21. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109), 629–634 (1997).
Medline CASGoogle Scholar
22. Jensen MC, Popplewell L, Cooper LJ et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol. Blood Marrow Transplant. 16(9), 1245–1256 (2010).
Medline CASGoogle Scholar
23. Kochenderfer JN, Dudley ME, Feldman SA et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119(12), 2709–2720 (2012).
Medline CASGoogle Scholar
24. Kochenderfer JN, Dudley ME, Carpenter RO et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 122(25), 4129–4139 (2013).
Medline CASGoogle Scholar
25. Kochenderfer JN, Dudley ME, Kassim SH et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol. 33(6), 540–549 (2015).
Medline CASGoogle Scholar
26. Turtle CJ, Hanafi LA, Berger C et al. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci. Transl. Med. 8(355), 355ra116 (2016).
MedlineGoogle Scholar
27. Brudno JN, Somerville RP, Shi V et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J. Clin. Oncol. 34(10), 1112–1121 (2016).
Medline CASGoogle Scholar
28. Wang X, Popplewell LL, Wagner JR et al. Phase I studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. Blood 127(24), 2980–2990 (2016).
Medline CASGoogle Scholar
29. Schuster SJ, Svoboda J, Chong EA et al. Chimeric antigen receptor T cells in refractory B-Cell lymphomas. N. Engl. J. Med. 377(26), 2545–2554 (2017).
Medline CASGoogle Scholar
30. Kochenderfer JN, Somerville RPT, Lu T et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. J. Clin. Oncol. 35(16), 1803–1813 (2017).
Medline CASGoogle Scholar
31. Ramos CA, Rouce R, Robertson CS et al. In vivo fate and activity of second- versus third-generation CD19-specific CAR-T cells in B Cell nonHodgkin's lymphomas. Mol. Ther. 26(12), 2727–2737 (2018).
Medline CASGoogle Scholar
32. Enblad G, Karlsson H, Gammelgård G et al. A Phase I/IIa trial using CD19-targeted third-generation CAR-T cells for lymphoma and leukemia. Clin. Cancer Res. 24(24), 6185–6194 (2018).
Medline CASGoogle Scholar
33. Hirayama AV, Gauthier J, Hay KA et al. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR-T cells. Blood 133(17), 1876–1887 (2019).
Medline CASGoogle Scholar
34. Sauter CS, Senechal B, Rivière I et al. CD19 CAR-T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma. Blood 134(7), 626–635 (2019).
Medline CASGoogle Scholar
35. Hirayama AV, Gauthier J, Hay KA et al. High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. Blood 134(7), 636–640 (2019).
Medline CASGoogle Scholar
36. Ying Z, Huang XF, Xiang X et al. A safe and potent anti-CD19 CAR-T cell therapy. Nat. Med. 25(6), 947–953 (2019).
Medline CASGoogle Scholar
37. Brudno JN, Lam N, Vanasse D et al. Safety and feasibility of anti-CD19 CAR-T cells with fully human binding domains in patients with B-cell lymphoma. Nat. Med. 26(2), 270–280 (2020).
Medline CASGoogle Scholar
38. Wang M, Munoz J, Goy A et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 382(14), 1331–1342 (2020).
Medline CASGoogle Scholar
39. Cao JX, Gao WJ, You J, Wu LH, Liu JL, Wang ZX. The efficacy of anti-CD19 chimeric antigen receptor T cells for B-cell malignancies. Cytotherapy 21(7), 769–781 (2019). • A meta-analysis of CD19 CAR-T cell for B-cell malignancies indicates that the best ORR of lymphoma was 68%, and shows the difference of the best ORR between received IL-2 and not receive IL-2 was not statistical significance.
Medline CASGoogle Scholar
40. Qasim W. Allogeneic CAR-T cell therapies for leukemia. Am. J. Hematol. 94(S1), S50–S54 (2019).
Medline CASGoogle Scholar
41. Xu Y, Li S, Wang Y et al. Induced CD20 expression on B-cell malignant cells heightened the cytotoxic activity of chimeric antigen receptor engineered T cells. Hum. Gene Ther. 30(4), 497–510 (2019).
Medline CASGoogle Scholar
42. Nagle K, Tafuto B, Palladino Kim L, Parrott JS. Effect of transplant status in CD19-targeted CAR T-cell therapy: a systematic review and meta-analysis. Med. Oncol. 35(11), 144 (2018).
MedlineGoogle Scholar
43. Liu J, Zhong JF, Zhang X, Zhang C. Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies. J. Hematol. Oncol. 10(1), 35 (2017).
MedlineGoogle Scholar
44. Neelapu SS, Tummala S, Kebriaei P et al. Chimeric antigen receptor T-cell therapy – assessment and management of toxicities. Nat. Rev. Clin. Oncol. 15(1), 47–62 (2018).
Medline CASGoogle Scholar
45. Hunter BD, Jacobson CA. CAR T-Cell associated neurotoxicity: mechanisms, clinicopathologic correlates, and future directions. J. Natl Cancer Inst. 111(7), 646–654 (2019).
MedlineGoogle Scholar

Vol. 13, No. 4

Metrics

Downloaded 424 times

History

Received 30 July 2020

Accepted 7 December 2020

Published online 7 January 2021

Published in print March 2021

Information

Keywords

Author contributions

Author F Liu and N Wang were responsible for study conception and design; authors F Liu, N Wang and Y Meng were responsible for acquisition of data and drafting and revision of the manuscript; authors F Liu, N Wang, Y Meng, Y Wu, J He were responsible for data analysis; authors F Liu, N Wang, Y Meng, Y Wu, J He were responsible for final approval of the version to be published.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

This article does not contain any studies with human participants or animals performed by any of the authors.

PDF download